Rheumatology 2015 The British Society for Rheumatology and British Health Professionals in Rheumatology Annual Meeting 2015 28 April – 30 April 2015 Manchester Central, Manchester, UK The abstracts are freely available online to all visitors to the Rheumatology website (http://www.rheumatology.oxfordjournals.org). RheumatologyDOI is incorrect10.1093/rheumatology/ker000ker000ContentsRheumatologyContents- Contents2012000000002012Volume 51 Supplement 3 May 2012 Volume 54 Supplement 1 April 2015 CONTENTS Rheumatology 2015 Abstracts INVITED SPEAKER ABSTRACTS (TUESDAY 28 APRIL 2015) I01–I03 Imaging in rheumatology: a practical perspective i1 I04–I06 Biologics in SLE: getting close to lift off (at last!) i1 I07–I09 Shared decision making and self-management support: why they matter in i1 rheumatology I10–I11 Challenges of remote and rural rheumatology i2 I12–I15 A step in the right direction: addressing foot health in rheumatoid arthritis i2 I16–I18 Musculoskeletal health and vocational rehabilitation i3 I19–I21 Making it happen: optimizing the service to RA patients i4 I22–I24 Community-based physical activity for osteoarthritis: the emerging role of i4 non-healthcare professionals I25–I26 Post-doctoral, PhD and postgraduate student network i5 I27–I32 Jewels in the Crown and top scoring abstracts (including Michael Mason and Garrod i5 prize winners and young investigator award) I33 Heberden Round i6 INVITED SPEAKER ABSTRACTS (WEDNESDAY 29 APRIL 2015) I34–I36 Pain in the 21st century: sensory–immune interactions, biologic agents and i8 bisphosphonates I37–I39 The British Society for Immunology: not the usual suspects: novel players in immune i8 homeostasis I40–I42 Essentials in rheumatology: disease assessment and management i9 I43–I45 Quality not quantity: research training in qualitative methods i9 I46–I49 Comorbidities in rheumatoid arthritis i10 I50–I54 BHPR workshop: measuring disease activity in axial spondyloarthropathy and ankylosing i10 spondylitis I55–I57 Hypermobility: a pain to manage? i11 I58–I60 The British Society for Immunology: Infection and autoimmunity: the missing links i11 I61–I63 Essentials in rheumatology: clinical knowledge and practice i12 I64–I66 Diagnosis and management of common shoulder problems in primary care i12 I67–I70 Specialized services commissioning: what’s in it for rheumatology? i13 I71–I72 BRiTs: adolescent rheumatology: what rheumatology trainees need to know i13 I73–I75 The gut microbiome and inflammatory arthritis i14 I76–I77 Essentials in rheumatology: update from the experts i14 I78–I80 Improving quality of life for older adults with musculoskeletal conditions i14 I81 Heberden Oration i15 www.rheumatology.oxfordjournals.org INVITED SPEAKER ABSTRACTS (THURSDAY 30 APRIL 2015) I82–I84 Pharmacoepidemiology: new truths, new lies i16 I85–I87 How to write, review and edit for rheumatology journals i16 I88–I90 Ageing well: is it about bone or muscle or both? i17 I91–I93 Adolescent and young adult rheumatology i18 I94–I96 How can we encourage patient participation in the clinic? i18 I97–I99 Rheumatic disease and the kidney i18 I100–I101 BRiTs: seronegative arthritides: test your knowledge! i19 I102–I104 BSR clinical guidelines i19 I105 Droitwich Medical Trust Lecture i19 I106–I108 Opportunistic infections i19 I109–I110 BRiTs: dermatological manifestations of rheumatic disease: all you i20 need to know I111–I113 The challenge of public education in rheumatology i20 I114–I116 Get fired up for audit and research i20 I117–I119 From TNF inhibition to biosimilars: managing safety and quality i21 BSR AND BHPR ORAL PRESENTATION OF ABSTRACTS (TUESDAY 28 APRIL 2015) O01–O06 RA outcomes and comorbidities and Young Investigator Prize winner i22 O07–O12 Biologics and inflammatory arthritis i25 BSR AND BHPR ORAL PRESENTATION OF ABSTRACTS (WEDNESDAY 29 APRIL 2015) O13–O18 Connective tissue diseases i30 O19–O24 Imaging i33 O25–O30 BHPR i35 O31–O36 Primary care i38 BSR AND BHPR ORAL PRESENTATION OF ABSTRACTS (THURSDAY 30 APRIL 2015) O37–O42 Basic science i41 O43–O48 Adolescent and young adult rheumatology i44 O49–O54 Genetics i47 POSTER VIEWING I (TUESDAY 28 APRIL 2015) 001–026 Case reports i50 027–044 Epidemiology i59 045–051 Primary care i66 052–055 Rheumatoid arthritis: pathogenesis i69 056–080 Rheumatoid arthritis: treatment i71 081–089 Rheumatoid arthritis: clinical features i82 090–107 Rheumatoid arthritis: comorbidities i85 108–113 Miscelleaneous rheumatic diseases i93 POSTER VIEWING II (WEDNESDAY 29 APRIL 2015) 114–140 BHPR audit and clinical evaluation and BHPR Clinical Prize winner i96 141–155 BHPR research: qualitative i105 156–164 BHPR research: quantitative i111 165–185 Health services research, economics and outcomes research i114 186–189 Muscle disorders i122 190–191 Orthopaedics and rehabilitation i123 192–194 Osteoarthritis: clinical features i124 195 Osteoarthritis: pathogenesis i125 196–201 Osteoarthritis: treatment i125 202–212 Osteoporosis and metabolic bone disease i128 213–216 Sjo¨ gren’s syndrome and other connective tissue disorders i131 217–231 Spondyloarthropathies (including psoriatic arthritis) i133 232–235 Soft tissue and regional musculoskeletal disease, fibromyalgia i139 POSTER VIEWING III (THURSDAY 30 APRIL 2015) 236 Basic science i142 237–238 Biology of bone cartilage and connective tissue i142 239–240 Cytokines and inflammation i143 241–251 Education i143 252–259 Genetics i148 260–262 Imaging i151 263–265 Metabolic and crystal arthropathies i152 266–277 Paediatric and adolescent rheumatology i153 www.rheumatology.oxfordjournals.org 278–281 Pain i158 282–288 Scleroderma and related disorders i159 289–303 Systemic lupus erythematosus and antiphospholipid syndrome i162 304–318 Vasculitis i168 E-POSTER ABSTRACTS E01–E26 Abstracts i175 E27–E28 Epidemiology i182 E29–E30 Health services research, economics and outcomes research i183 E31 Primary care i184 E32 Rheumatoid arthritis: pathogenesis i184 E33–E52 Rheumatoid arthritis: treatment i184 E53 Rheumatoid arthritis: clinical features i192 E54–E57 Rheumatoid arthritis: comorbidities i192 E59 Miscellaneous rheumatic diseases i193 E60–E65 BHPR: Audit and clinical evaluation i193 E66 BHPR Research: qualitative i195 E67 Orthopaedics and rehabilitation i196 E68 Osteoarthritis: clinical features i196 E69 Osteoarthritis: pathogenesis i196 E70–E71 Osteoarthritis: treatment i196 E72–E73 Osteoporosis and metabolic bone disease i197 E74–E77 Spondylarthropathies (including psoriatic arthritis) i198 E78–E81 Soft tissue and regional musculoskeletal disease, fibromyalgia i199 E82 Basic science i200 E83-E85 Education i201 E86 Imaging i202 E87–E88 Metabolic and crystal arthropathies i202 E89–E95 SLE and antiphospholipid syndrome i203 E96 Vasculitis i205 ABSTRACT REVIEWERS i206 AUTHOR INDEX i207 Every effort has been made to faithfully reproduce the abstracts as submitted. However, no responsibility is assumed by the organizers for any injury and/or damage to persons or property as a matter of product liability, negligence or otherwise, or from any use or operation of any methods, products, instructions or ideas contained in the material herein. Because of rapid advances in the medical sciences, we recommend that independent verification of diagnoses and drug doses should be made. www.rheumatology.oxfordjournals.org i1 Tuesday 28 April 2015 INVITED SPEAKER ABSTRACTS patients have required regular oral steroids. Another small report of non-renal lupus also confirmed the potential reduction in oral steroids IMAGING IN RHEUMATOLOGY: over the 6 months following diagnosis and an equivalent clinical benefit A PRACTICAL PERSPECTIVE compared with those given conventional steroids and immunosup- pression. Several further trials of rituximab or an equivalent fully humanized monoclonal anti-CD20 are now envisaged. As an alter- native, epratuzumab (which blocks the CD22 molecule on B cells) has I01. BACK PAIN: WHEN TO (AND NOT TO) IMAGE shown some encouraging results in a provisional trial using the BILAG- based Composite Lupus Assessment disease activity assessment Philip Helliwell1 tool. Interestingly, only some dose regimens were effective, but the 1Leeds Institute of Rheumatic and Musculoskeletal Medicine, results were sufficiently compelling to encourage the pharmaceutical University of Leeds, Leeds, UK company concerned to undertake two large international trials of epratuzumab; these results are awaited with great interest. The sense Non-invasive tomographic imaging, such as MRI and CT, has enabled of frustration around the use of B cell depletion in lupus has been better quality care for people with back pain. However, this has come palpable. The early encouraging signs allied to its successful use in at a cost, both financial and medical. On the positive side, there is other related conditions notably RA and vasculitis led to the hope that better diagnostic imaging and better targeted therapy. On the negative B cell depletion would be generally accepted as a viable treatment side, there is overdiagnosis and sometimes overtreatment. Guidelines method. The failure of the EXPLORER and LUNAR studies threatened for the use of plain radiography in back pain have been drawn up to to call a halt to this form of treatment, but more encouraging recent avoid unnecessary radiation and inappropriate imaging. Examples will studies have again rekindled the hope this is a variable therapeutic be given to illustrate these points and the question asked: should approach. From the regulatory perspective however the jury is still out. equivalent guidelines be developed